Off-label promotion and prescribing of gabapentin [2]

Australian Prescriber

Volumn 26, Issue 2, 2003, Pages 28-

  Lam, William ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; VIGABATRIN;

ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; HUMAN; LETTER; NEUROPATHIC PAIN; PRESCRIPTION; VISUAL FIELD DEFECT;

EID: 0037246125     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. In: The Cochrane Library, 4, 2002. Oxford: Update Software.
2. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
3. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
4. Rice AS, Maton S. Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
5. Serpell MG. Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66.
6. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromusc Dis 2001;3:53-62.
7. Sweet M. Gabapentin documents raise concerns about off-label promotion and prescribing. Aust Prescr 2003;26:18-9.